Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer

Free Radical Biology and Medicine

Volumn 50, Issue 11, 2011, Pages 1610-1619

  Espey, Michael Graham ^a   Chen, Ping ^b,c   Chalmers, Brian ^b   Drisko, Jeanne ^b   Sun, Andrew Y ^a   Levine, Mark ^a   Chen, Qi ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Ascorbate; Drug synergy; Free radicals; Gemcitabine; Pancreatic cancer; Vitamin C

Indexed keywords

ASCORBIC ACID; BIOLOGICAL MARKER; GEMCITABINE; HYDROGEN PEROXIDE; MESSENGER RNA; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIZATION; EXPERIMENTAL DESIGN; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCORBIC ACID; CARCINOMA; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 79955603438     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2011.03.007     Document Type: Article

References (60)

1. Cancer Facts and Figures 20 2009 American Cancer Society Atlanta
2. D. Li, K. Xie, R. Wolff, and J.L. Abbruzzese Pancreatic cancer Lancet 363 2004 1049 1057 (Pubitemid 38410779)
3. J. Nieto, M.L. Grossbard, and P. Kozuch Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13 2008 562 576 (Pubitemid 351872873)
4. E. Mini, S. Nobili, B. Caciagli, I. Landini, and T. Mazzei Cellular pharmacology of gemcitabine Ann. Oncol. 17 Suppl. 5 2006 v7 v12
5. H. Oettle, S. Post, P. Neuhaus, K. Gellert, J. Langrehr, K. Ridwelski, H. Schramm, J. Fahlke, C. Zuelke, C. Burkart, K. Gutberlet, E. Kettner, H. Schmalenberg, K. Weigang-Koehler, W.O. Bechstein, M. Niedergethmann, I. Schmidt-Wolf, L. Roll, B. Doerken, and H. Riess Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 2007 267 277 (Pubitemid 46143304)
6. D. Renouf, and M. Moore Evolution of systemic therapy for advanced pancreatic cancer Expert Rev. Anticancer Ther. 10 2010 529 540
7. F. Rivera, S. Lopez-Tarruella, M.E. Vega-Villegas, and M. Salcedo Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy Cancer Treat. Rev. 35 2009 335 339
8. Q. Chen, M.G. Espey, A.Y. Sun, J.H. Lee, M.C. Krishna, E. Shacter, P.L. Choyke, C. Pooput, K.L. Kirk, G.R. Buettner, and M. Levine Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo Proc. Natl Acad. Sci. U. S. A. 104 2007 8749 8754 (Pubitemid 47175383)
9. S.J. Padayatty, H. Sun, Y. Wang, H.D. Riordan, S.M. Hewitt, A. Katz, R.A. Wesley, and M. Levine Vitamin C pharmacokinetics: implications for oral and intravenous use Ann. Intern. Med. 140 2004 533 537
10. L.J. Hoffer, M. Levine, S. Assouline, D. Melnychuk, S.J. Padayatty, K. Rosadiuk, C. Rousseau, L. Robitaille, and W.H. Miller Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy Ann. Oncol. 19 2008 1969 1974
11. S.J. Padayatty, A.Y. Sun, Q. Chen, M.G. Espey, J. Drisko, and M. Levine Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects PLoS ONE 5 2010 e11414
12. Q. Chen, M.G. Espey, A.Y. Sun, C. Pooput, K.L. Kirk, M.C. Krishna, D.B. Khosh, J. Drisko, and M. Levine Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice Proc. Natl Acad. Sci. U. S. A. 105 2008 11105 11109
13. M. Levine, M.G. Espey, and Q. Chen Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment Free Radic. Biol. Med. 47 2009 27 29
14. J. Verrax, and P.B. Calderon Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects Free Radic. Biol. Med. 47 2009 32 40
15. Q. Chen, M.G. Espey, M.C. Krishna, J.B. Mitchell, C.P. Corpe, G.R. Buettner, E. Shacter, and M. Levine Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues Proc. Natl Acad. Sci. U. S. A. 102 2005 13604 13609 (Pubitemid 41420895)
16. Y. Takemura, M. Satoh, K. Satoh, H. Hamada, Y. Sekido, and S. Kubota High dose of ascorbic acid induces cell death in mesothelioma cells Biochem. Biophys. Res. Commun. 394 2010 249 253
17. J. Du, S.M. Martin, M. Levine, B.A. Wagner, G.R. Buettner, S.H. Wang, A.F. Taghiyev, C. Du, C.M. Knudson, and J.J. Cullen Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer Clin. Cancer Res. 16 2010 509 520
18. H.B. Pollard, M.A. Levine, O. Eidelman, and M. Pollard Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer In Vivo 24 2010 249 255
19. 2-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin Cell. Physiol. Biochem. 25 2010 767 774
20. A. Fromberg, D. Gutsch, D. Schulze, C. Vollbracht, G. Weiss, F. Czubayko, A. Aigner, Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother. Pharmacol; 2010 Aug. 8. [Electronic publication ahead of print].
21. S. Belin, F. Kaya, G. Duisit, S. Giacometti, J. Ciccolini, and M. Fontes Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression PLoS ONE 4 2009 e4409
22. Z.Y. Lin, and W.L. Chuang Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines Biomed. Pharmacother. 64 2010 348 351
23. J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res. 47 1987 936 942 (Pubitemid 17027905)
24. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
25. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
26. T.C. Chou, and P. Talalay Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors Eur. J. Biochem. 115 1981 207 216
27. T. Arumugam, V. Ramachandran, K.F. Fournier, H. Wang, L. Marquis, J.L. Abbruzzese, G.E. Gallick, C.D. Logsdon, D.J. McConkey, and W. Choi Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer Cancer Res. 69 2009 5820 5828
28. R. Kalluri, and R.A. Weinberg The basics of epithelial-mesenchymal transition J. Clin. Invest. 119 2009 1420 1428
29. C. Louvet, T. Andre, G. Lledo, P. Hammel, H. Bleiberg, C. Bouleuc, E. Gamelin, M. Flesch, E. Cvitkovic, and A. de Gramont Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study J. Clin. Oncol. 20 2002 1512 1518 (Pubitemid 34260530)
30. H. Masuda, T. Tanaka, and U. Takahama Cisplatin generates superoxide anion by interaction with DNA in a cell-free system Biochem. Biophys. Res. Commun. 203 1994 1175 1180 (Pubitemid 24304953)
31. S. Kopetz, D.P. Lesslie, N.A. Dallas, S.I. Park, M. Johnson, N.U. Parikh, M.P. Kim, J.L. Abbruzzese, L.M. Ellis, J. Chandra, and G.E. Gallick Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress Cancer Res. 69 2009 3842 3849
32. K.N. Prasad, P.K. Sinha, M. Ramanujam, and A. Sakamoto Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture Proc. Natl Acad. Sci. U. S. A. 76 1979 829 832 (Pubitemid 9130954)
33. P. Hakansson, A. Hofer, and L. Thelander Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells J. Biol. Chem. 281 2006 7834 7841 (Pubitemid 43847398)
34. H. Tanaka, H. Arakawa, T. Yamaguchi, K. Shiraishi, S. Fukuda, K. Matsui, Y. Takei, and Y. Nakamura A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage Nature 404 2000 42 49 (Pubitemid 30143125)
35. L. Xue, B. Zhou, X. Liu, T. Wang, J. Shih, C. Qi, Y. Heung, and Y. Yen Structurally dependent redox property of ribonucleotide reductase subunit p53R2 Cancer Res. 66 2006 1900 1905
36. T.P. Yeo, R.H. Hruban, S.D. Leach, R.E. Wilentz, T.A. Sohn, S.E. Kern, C.A. Iacobuzio-Donahue, A. Maitra, M. Goggins, M.I. Canto, R.A. Abrams, D. Laheru, E.M. Jaffee, M. Hidalgo, and C.J. Yeo Pancreatic cancer Curr. Probl. Cancer 26 2002 176 275
37. C.E. Cross, B. Halliwell, E.T. Borish, W.A. Pryor, B.N. Ames, R.L. Saul, J.M. McCord, and D. Harman Oxygen radicals and human disease Ann. Intern. Med. 107 1987 526 545
38. H.J. Palmer, and K.E. Paulson Reactive oxygen species and antioxidants in signal transduction and gene expression Nutr. Rev. 55 1997 353 361 (Pubitemid 27487423)
39. M.W. Lawless, K.J. O'Byrne, and S.G. Gray Targeting oxidative stress in cancer Expert Opin. Ther. Targets 14 2010 1225 1245
40. O. Warburg, F. Wind, and E. Negelein The metabolism of tumors in the body J. Gen. Physiol. 8 1927 519 530
41. H. Pelicano, D.S. Martin, R.H. Xu, and P. Huang Glycolysis inhibition for anticancer treatment Oncogene 25 2006 4633 4646 (Pubitemid 44187614)
42. R.H. Xu, H. Pelicano, Y. Zhou, J.S. Carew, L. Feng, K.N. Bhalla, M.J. Keating, and P. Huang Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia Cancer Res. 65 2005 613 621
43. P.A. Hyslop, D.B. Hinshaw, W.A. Halsey Jr., I.U. Schraufstatter, R.D. Sauerheber, R.G. Spragg, J.H. Jackson, and C.G. Cochrane Mechanisms of oxidant-mediated cell injury: the glycolytic and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide J. Biol. Chem. 263 1988 1665 1675 (Pubitemid 18052113)
44. 2 mediate glucose deprivation-induced stress in human cancer cells J. Biol. Chem. 280 2005 4254 4263 (Pubitemid 40288592)
45. M. Comelli, F. Di Pancrazio, and I. Mavelli Apoptosis is induced by decline of mitochondrial ATP synthesis in erythroleukemia cells Free Radic. Biol. Med. 34 2003 1190 1199 (Pubitemid 36423368)
46. G.A. Hyman Anemia in malignant neoplastic disease J. Chronic Dis. 16 1963 645 666
47. S. Kovac, G.J. Anderson, G.S. Baldwin, Gastrins, iron homeostasis and colorectal cancer. Biochim. Biophys. Acta; 2011 Feb. 12. [Electronic publication ahead of print].
48. B.N. Ames DNA damage from micronutrient deficiencies is likely to be a major cause of cancer Mutat. Res. 475 2001 7 20 (Pubitemid 32284938)
49. I.U. Schraufstatter, D.B. Hinshaw, P.A. Hyslop, R.G. Spragg, and C.G. Cochrane Oxidant injury of cells: DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide J. Clin. Invest. 77 1986 1312 1320 (Pubitemid 16047155)
50. Y.J. Lee, and E. Shacter Oxidative stress inhibits apoptosis in human lymphoma cells J. Biol. Chem. 274 1999 19792 19798
51. I.U. Schraufstatter, D.B. Hinshaw, P.A. Hyslop, R.G. Spragg, and C.G. Cochrane Glutathione cycle activity and pyridine nucleotide levels in oxidant-induced injury of cells J. Clin. Invest. 76 1985 1131 1139 (Pubitemid 16225562)
52. K.A. Brand, and U. Hermfisse Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species FASEB J. 11 1997 388 395 (Pubitemid 27193945)
53. C.V. Dang, and G.L. Semenza Oncogenic alterations of metabolism Trends Biochem. Sci. 24 1999 68 72 (Pubitemid 29346576)
54. G. Kroemer Mitochondria in cancer Oncogene 25 2006 4630 4632 (Pubitemid 44187613)
55. E.T. Creagan, C.G. Moertel, J.R. O'Fallon, A.J. Schutt, M.J. O'Connell, J. Rubin, and S. Frytak Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial N. Engl. J. Med. 301 1979 687 690 (Pubitemid 10240445)
56. C.G. Moertel, T.R. Fleming, E.T. Creagan, J. Rubin, M.J. O'Connell, and M.M. Ames High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison N. Engl. J. Med. 312 1985 137 141 (Pubitemid 15192859)
57. S.J. Padayatty, and M. Levine Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity J. Am. Coll. Nutr. 19 2000 423 425 (Pubitemid 30629145)
58. D. Li, and J.L. Abbruzzese New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts Clin. Cancer Res. 16 2010 4313 4318
59. M.L. Heaney, J.R. Gardner, N. Karasavvas, D.W. Golde, D.A. Scheinberg, E.A. Smith, and O.A. O'Connor Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs Cancer Res. 68 2008 8031 8038
60. M.G. Espey, Q. Chen, and M. Levine Comment re: Vitamin C antagonizes the cytotoxic effects of chemotherapy Cancer Res. 69 2009 8830 author reply 8830-8831